FDA Investigator Annemarie B Randow

Annemarie B Randow has conducted inspections on 19 sites in 1 countries as of 03 May 2006. See below for a list of the FDA enforcement documents resulting from those inspections.

Investigator Details

Number of Inspected Sites:
19
Last Inspection Date:
03 May 2006
Investigator Role:
FDA Investigation Participant
Redica ID:
100002041
Countries of Inspections:
United States of America
FDA Investigators that have inspected at least one site in common with Annemarie B Randow:
Addam S Reynolds, Adetutu M Gidado, Alberto A Viciedo, Amy L Singer, Amy M Codella, Amy M Cramer, Annemarie Bodnar, Atul J Agrawal, Barbara J Maulfair, Barbara Jwilimczyk Macri, Byungja E Marciante, Cassandra L Abellard, Daniel J Grabicki, Dawn L Wydner, Deborah B Goffman, Denise M Visco, Investigator, Dhaval H Patel, Doreen P Gubbay, Douglas C Kovacs, Emest F Bizjak, Eric Rothschild, Erin D Mccaffery, Frank J Marciniak, Frederick F Razzaghi, Gianine E Tompkins, Guerlain Ulysse, Helen Verdel, James R Birkenstamm, Janet A Rajan, Jean M Kelahan, Jeffrey J Ebersole, Jenny Sung, Jessica S Estriplet, Jogy George, Jonathan S Helfgott, Jose M Cayuela, Joy Rkozlowski Klena, Julie D Bringger, Justine Tomasso, Karen E D'orazio, Keith M Reilly, Kelli F Dobilas, Kinh Q Mac, Kristy A Zielny, Lauren L Vajo, Liatte Kreuger, PharmD, Lisa M Bellows, Lisa M Feola, Loretta Nemchik, Marea K Harmon, Margaret M Sands, Maria A Bienkowski, Maria A Reed, Maria Estrella, Marie B Buen Bigornia, Matthew A Spataro, Melba Trivera Clavell, Melissa T Roy, Meredith L Sheridan, Meyer J Slobotsky, Michael R Klapal, Nancy F Scheraga, Nancy L Rolli, Nancy M Espinal, Nerizza B Guerin, Nicholas A Violand, Patrick C Klotzbuecher, Paul L Bellamy, Paul Mouris, Peter R Lenahan, Regina T Brown, Rose Ljean Mary, Russell J Glapion, Samir C Gala, Sarah Forney, Satheesh K Podaralla, Schultz, Sean G Casey, Shirley H Isbill, Sinai I Davis, Stephanie T Durso, Stephen J Mottola, Stephenie M Ortiz, Steven P Donald, Suchan Kim, Tara G Bizjak, Tara R Gooen, Tiffani D Wilson, Tonia F Bernard, Victoria Spivak

Annemarie B Randow's Documents

Publish Date Document Type Title
June, 2002 FDA 483 Alcami Corporation - Form 483, 2002-06-10
February, 2004 EIR Novus Fine Chemicals - EIR, 2004-02-18
February, 2003 EIR L'OREAL USA PRODUCTS, INC. - EIR, 2003-02-26
March, 2004 EIR OHM LABORATORIES INC. - EIR, 2004-03-01
April, 2004 EIR L'OREAL USA, INC. - EIR, 2004-04-27
June, 2002 EIR Medpointe Healthcare, Inc. - EIR, 2002-06-06
May, 2003 FDA 483 Able Laboratories, Inc. - Form 483, 2003-05-20
February, 2004 FDA 483 Novus Fine Chemicals - Form 483, 2004-02-18
November, 2003 FDA 483 Chromak Research, Inc. - Form 483, 2003-11-13
March, 2002 EIR Hudson Cosmetics Manufacturing Corp. DBA Paramount Cosmetics - EIR, 2002-03-12
April, 2002 EIR Medpointe Healthcare, Inc. - EIR, 2002-04-16
January, 2003 FDA 483 Response L'OREAL USA, INC. - Form 483R, 2003-02-03
February, 2004 FDA 483 Response Novus Fine Chemicals - Form 483R, 2004-03-08
May, 2006 FDA 483 Merck, Inc. - Form 483, 2006-05-25
May, 2002 FDA 483 OHM LABORATORIES INC. - Form 483, 2002-05-06
April, 2003 EIR Domanth Inc - EIR, 2003-04-04
June, 2002 FDA 483 Response Medpointe Healthcare, Inc. - Form 483R, 2002-06-25
May, 2002 FDA 483 Response OHM LABORATORIES INC. - Form 483R, 2002-05-24
June, 2002 FDA 483 Medpointe Healthcare, Inc. - Form 483, 2002-06-06
November, 2003 FDA 483 Response Chromak Research, Inc. - Form 483R, 2003-11-14
November, 2003 EIR Chromak Research, Inc. - EIR, 2003-11-13
September, 2003 EIR Pfizer Inc. - EIR, 2003-09-18
April, 2003 FDA 483 Domanth Inc - Form 483, 2003-04-04
July, 2003 FDA 483 Polarome International - Form 483, 2003-07-17
May, 2002 EIR OHM LABORATORIES INC. - EIR, 2002-05-06
May, 2003 EIR Able Laboratories, Inc. - EIR, 2003-05-20
June, 2002 EIR Alcami Corporation - EIR, 2002-06-10
January, 2003 EIR L'OREAL USA, INC. - EIR, 2003-01-22
June, 2003 EIR J. Knipper and Company, Inc. - EIR, 2003-06-11
March, 2003 EIR Hikma Pharmaceuticals USA, Inc. - EIR, 2003-03-12
December, 2003 EIR Blispak, Inc. - EIR, 2003-12-03
January, 2003 FDA 483 L'OREAL USA, INC. - Form 483, 2003-01-22

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more